Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
32.66
+1.23 (3.91%)
Jan 17, 2025, 4:00 PM EST - Market closed
Legend Biotech Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Legend Biotech stock have an average target of 80.62, with a low estimate of 60 and a high estimate of 94. The average target predicts an increase of 146.85% from the current stock price of 32.66.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $78 | Buy | Reiterates | $78 | +138.82% | Dec 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +123.52% | Dec 10, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $83 | Buy | Reiterates | $83 | +154.13% | Dec 9, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $86 | Buy | Reiterates | $86 | +163.32% | Dec 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +123.52% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
628.33M
from 285.14M
Increased by 120.36%
Revenue Next Year
1.06B
from 628.33M
Increased by 67.91%
EPS This Year
-1.07
from -2.94
EPS Next Year
-0.64
from -1.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 676.9M | 1.3B | 2.0B | |||
| Avg | 628.3M | 1.1B | 1.6B | |||
| Low | 575.8M | 842.8M | 1.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 137.4% | 99.6% | 86.8% | |||
| Avg | 120.4% | 67.9% | 50.3% | |||
| Low | 101.9% | 34.1% | 14.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.71 | -0.28 | 1.22 | |||
| Avg | -1.07 | -0.64 | 0.33 | |||
| Low | -1.58 | -1.27 | 0.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.